hexavalent OX40 agonist ordastobart (INBRX-106) with Keytruda (pembrolizumab)- (HexAgon-HN)

Oct. 13, 2026: Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced upcoming conference presentations for multiple oncology programs.

Ordastobart (INBRX-106): At the 2026 ESMO Congress in Madrid on October 25, 2026, the company plans an oral presentation on the phase 2/3 HexAgon-HN study of the hexavalent OX40 agonist ordastobart plus pembrolizumab as first-line treatment for PD-L1-high recurrent/metastatic head and neck squamous cell carcinoma. The presentation will cover the phase 2 primary analysis.

Ozekibart (INBRX-109) in conventional chondrosarcoma: At the 2026 Musculoskeletal Tumor Society Annual Meeting in Miami on October 29, 2026, Inhibrx will give an oral presentation on secondary efficacy endpoints from the randomized, registrational phase 2 ChonDRAgon study. At the 2026 Connective Tissue Oncology Society Annual Meeting in Seoul on November 20, 2026, it will present subgroup analysis and updated progression-free survival from the randomized phase 2 ChonDRAgon study.

Ozekibart (INBRX-109) in Ewing sarcoma: At the 2026 CTOS Annual Meeting on November 19, 2026, Inhibrx will present a poster on a phase 1/2 study of ozekibart combined with irinotecan and temozolomide in adolescents and adults with Ewing sarcoma.